These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 25300859)

  • 1. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.
    Ohkuri T; Ghosh A; Kosaka A; Zhu J; Ikeura M; David M; Watkins SC; Sarkar SN; Okada H
    Cancer Immunol Res; 2014 Dec; 2(12):1199-208. PubMed ID: 25300859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
    Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
    ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
    Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice.
    Wang Z; Celis E
    Cancer Immunol Immunother; 2015 Aug; 64(8):1057-66. PubMed ID: 25986168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.
    Fujita M; Scheurer ME; Decker SA; McDonald HA; Kohanbash G; Kastenhuber ER; Kato H; Bondy ML; Ohlfest JR; Okada H
    Clin Cancer Res; 2010 Jul; 16(13):3409-19. PubMed ID: 20472682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses.
    Huang L; Li L; Lemos H; Chandler PR; Pacholczyk G; Baban B; Barber GN; Hayakawa Y; McGaha TL; Ravishankar B; Munn DH; Mellor AL
    J Immunol; 2013 Oct; 191(7):3509-13. PubMed ID: 23986532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
    Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
    Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer.
    Chandra D; Quispe-Tintaya W; Jahangir A; Asafu-Adjei D; Ramos I; Sintim HO; Zhou J; Hayakawa Y; Karaolis DK; Gravekamp C
    Cancer Immunol Res; 2014 Sep; 2(9):901-10. PubMed ID: 24913717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
    Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
    Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
    Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
    Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
    Corrales L; Gajewski TF
    Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
    Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
    Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides.
    Sauer JD; Sotelo-Troha K; von Moltke J; Monroe KM; Rae CS; Brubaker SW; Hyodo M; Hayakawa Y; Woodward JJ; Portnoy DA; Vance RE
    Infect Immun; 2011 Feb; 79(2):688-94. PubMed ID: 21098106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The GRA15 protein from
    Wang P; Li S; Zhao Y; Zhang B; Li Y; Liu S; Du H; Cao L; Ou M; Ye X; Li P; Gao X; Wang P; Jing C; Shao F; Yang G; You F
    J Biol Chem; 2019 Nov; 294(45):16494-16508. PubMed ID: 31416833
    [No Abstract]   [Full Text] [Related]  

  • 16. Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy.
    Yu Y; Bogdan M; Noman MZ; Parpal S; Bartolini E; Van Moer K; Kleinendorst SC; Bilgrav Saether K; Trésaugues L; Silvander C; Lindström J; Simeon J; Timson MJ; Al-Hashimi H; Smith BD; Flynn DL; Alexeyenko A; Viklund J; Andersson M; Martinsson J; Pokrovskaja Tamm K; De Milito A; Janji B
    Mol Oncol; 2024 Aug; 18(8):1904-1922. PubMed ID: 38506049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.
    Vonderhaar EP; Barnekow NS; McAllister D; McOlash L; Eid MA; Riese MJ; Tarakanova VL; Johnson BD; Dwinell MB
    Cell Mol Gastroenterol Hepatol; 2021; 12(1):41-58. PubMed ID: 33548597
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Costa Franco MM; Marim F; Guimarães ES; Assis NRG; Cerqueira DM; Alves-Silva J; Harms J; Splitter G; Smith J; Kanneganti TD; de Queiroz NMGP; Gutman D; Barber GN; Oliveira SC
    J Immunol; 2018 Jan; 200(2):607-622. PubMed ID: 29203515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8
    Kosaka A; Yajima Y; Yasuda S; Komatsuda H; Nagato T; Oikawa K; Kobayashi H; Ohkuri T
    Int J Cancer; 2023 Apr; 152(8):1685-1697. PubMed ID: 36495276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer.
    Ni H; Zhang H; Li L; Huang H; Guo H; Zhang L; Li C; Xu JX; Nie CP; Li K; Zhang X; Xia X; Li J
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36126994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.